Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

Autor(es)

Cavalcante, Lucas de Sousa ^[1] ; Monteiro, Gisele ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, FCF, Dept Tecnol Bioquim Farmaceut, BR-05508000 Sao Paulo - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: European Journal of Pharmacology; v. 741, p. 8-16, OCT 15 2014.
• Citações Web of Science: 152

Resumo

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use, intrinsic and acquired chemoresistance is common. In general, the underlying mechanisms of chemoresistance are poorly understood. Here, current knowledge of gemcitabine metabolism, mechanisms of action, sensitivity and chemoresistance reported over the past two decades are reviewed; and we also offer new perspectives to improve gemcitabine efficacy with particular reference to the treatment of pancreatic cancer. (C) 2014 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 11/04938-8 - Identificação de alvos moleculares associados à resistência aos antitumorais Gemcitabina e análogos de Rebecamicina usando Saccharomyces cerevisiae como modelo celular
• Beneficiário: Lucas de Sousa Cavalcante
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 09/01303-1 - Caracterização de ORFs de função desconhecida envolvidas na resposta antioxidante em Saccharomyces cerevisiae
• Beneficiário: Gisele Monteiro
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores